Editorial Article
Methionine Is Priced by a Refinery Schedule, Phytase by a Rock, and Gut Health by Nothing at All
The least useful number in the feed additives market is the one everybody quotes. The market is worth USD 43,500.0 million and will be worth USD 62,900.0 million in 2033, which is 4.72 per cent a year, which is neither surprising nor actionable. The useful number is that two categories holding 26.0 per cent of the base deliver 50.0 per cent of the growth, and that the reason they do has nothing to do with what they do for the animal.
These are not one market. They are six, sharing a customer and almost nothing else. Amino acids are a chemical industry. Enzymes are a fermentation industry. Vitamins are a specialty chemistry with two credible sources. Gut health is a marketing industry constrained by a licensing regime. Prices in each are set by a different mechanism, and averaging them into a single growth rate is how forecasts end up wrong in opposite directions at the same time.
The full analysis, including the value chain, the regulatory record and the investment activity, is in our report on the Global Feed Additives Market. This article takes the pricing question on its own.
One: legal minima are priced by how few plants can make the molecule
A vitamin is bought because the animal requires it and, in most jurisdictions, because a minimum or maximum is written into feed law. Demand does not respond to price. When demand is inelastic, price is set on the supply side, and the supply side in this category is extraordinarily thin.
Vitamin A and the carotenoids share a synthesis route through citral and isophytol. On 29 July 2024 a fire damaged a plant at BASF’s Ludwigshafen site that manufactures aroma ingredients and precursors for vitamin A, vitamin E and carotenoid production. On 7 August 2024 BASF declared force majeure on deliveries of selected vitamin A, vitamin E and carotenoid products, and on a list of aroma ingredients that reads like a chemistry syllabus — ionones, pyranol, DL-menthol, rose oxides, ethyllinalool, nerolidol, isophytol R.
Nothing about demand changed on 29 July. What changed was that a repair schedule at one German site became a formulation constraint for every premixer in the world. That is what a concentrated supply base does to a product nobody can stop buying.
The financial signature of this mechanism is volatility inside a low average. Vitamins grow at 2.64 per cent across the eight years, the slowest of the six categories, and that average is the mean of a series of spikes and reversals that has never been smooth. A category that is dull on a chart is not a category that is safe in a supply chain.
Two: economic optima are capped by the nutrient they replace
An amino acid or an enzyme is bought because it is cheaper than the alternative. That single sentence determines the whole pricing structure, because it means the seller does not set the ceiling. The substitute does.
Phytase is the cleanest case in the category. It hydrolyses phytate and releases phosphorus the animal would otherwise excrete, which allows inorganic feed phosphate to be removed from the ration. The enzyme’s commercial value is therefore an arithmetic substitution against a mineral price, and that mineral price is set in the fertiliser and phosphate complex modelled separately in our Global Feed Phosphates report, upstream of which sits the Global Fertiliser (NPK) market. When phosphate salts are expensive, phytase’s headroom widens. When they are cheap, the headroom closes and only limits on phosphorus excretion keep the product in the ration.
The consequence is visible in the numbers. Enzymes grow at 7.07 per cent to USD 7,600.0 million by 2033 while their realised price stays subdued, because the growth is units rather than value per unit. That is the signature of a product priced against a substitute: strong volume, disciplined price, and a margin that belongs to whoever can ferment it cheapest.
Amino acids carry the same cap through a different route. Soybean meal is the protein the amino acid package displaces, and its price is set by oilseed planting decisions tracked in our Global Soybean Seed coverage. Cheaper meal narrows the economic case for precise supplementation. And the cap is moving toward the amino acid sellers rather than away: alternative proteins arrive with their own amino acid content. Insect meal produced at scale, as modelled in our Global Black Soldier Fly report, competes with the balancing package as well as with the oilseed meal it is meant to replace.
Three: a claim is priced against nothing measurable
The third mechanism is the one that produces both the growth and the margin, and it is worth stating precisely because it is unusual.
A gut-health product is bought to do a job that an antibiotic used to do. The antibiotic is no longer legal to sell for that purpose in the European Union, so the buyer has no legal substitute to price against. There is also no reference method to verify in a commercial mill that the product has worked. Performance attribution at flock level cannot separate one ingredient among twenty. So the ceiling is not a commodity price and not a competing product’s price. It is the buyer’s belief.
That is where the pricing power comes from, and it explains the apparently contradictory structure of the market. Methionine has nine suppliers worldwide, three of them holding almost 80 per cent of production. Gut health has dozens. The fragmented category earns the better growth rate — 8.65 per cent against 3.43 per cent for amino acids — and, on participants’ own reporting, the better gross margin. In this market, concentration and profitability run in opposite directions, which is the reverse of the usual industrial pattern.
| Mechanism | Categories | What sets the price | What caps it | CAGR to 2033 |
|---|---|---|---|---|
| Legal minimum | Vitamins, trace and macro minerals | Supply concentration and single-intermediate fragility | Nothing on the demand side | 2.64% and 3.62% |
| Economic optimum | Amino acids, enzymes | Cost of production and capacity discipline | The nutrient it replaces | 3.43% and 7.07% |
| Claim | Gut health and zootechnical additives | Absence of a legal substitute | Buyer belief, and the authorisation regime | 8.65% |
Why the concentration matters more than the growth rate
Methionine is the best-documented oligopoly in the category. Its production is fully chemical, from acrolein, hydrogen cyanide and methyl mercaptan, in plants that industry participants describe as resembling refineries and that must be taken down for major maintenance roughly every one to two years. On Adisseo‘s own account of the industry, the market is close to 1.8 to 1.9 million tonnes a year from nine suppliers, with the top three holding almost 80 per cent, and only three of the nine operating more than one plant.
That last detail is the whole commercial point. Evonik runs Belgium, Singapore and the United States; Adisseo runs powder capacity in France, liquid capacity in Spain, liquid capacity in China and new powder capacity in China; Novus International runs one United States plant; Sumitomo one in Japan; two Chinese producers one each; a Russian producer one; and CJ CheilJedang‘s Malaysian facility has been reported as closing. Nameplate capacity overstates real output because of those shutdowns, so price responds to a single plant’s outage rather than to demand.
Lysine is the mirror image and sits inside the same reported category. It is fermented from glucose, which means it tracks corn, energy and water, and capacity has migrated to wherever those are cheapest. The result is a structurally long market priced close to cash cost and repriced by capacity additions rather than outages. Methionine and lysine are averaged together in most published market sizes. They should not be.
| Category | 2025 (USD m) | 2033 (USD m) | CAGR |
|---|---|---|---|
| Amino acids | 14,200.0 | 18,600.0 | 3.43% |
| Trace and macro minerals | 7,300.0 | 9,700.0 | 3.62% |
| Gut health and zootechnical additives | 6,900.0 | 13,400.0 | 8.65% |
| Vitamins | 5,600.0 | 6,900.0 | 2.64% |
| Other technological and sensory additives | 5,100.0 | 6,700.0 | 3.47% |
| Enzymes | 4,400.0 | 7,600.0 | 7.07% |
| Total | 43,500.0 | 62,900.0 | 4.72% |
The price of a mole of methionine, and the price of a belief
Put the two ends of this market side by side and the anomaly is stark.
A methionine plant converts propylene, ammonia and methyl mercaptan into a molecule whose value to the buyer can be calculated against the soybean meal it allows the formulator to remove. Every buyer knows the arithmetic. The seller is one of nine, three of whom hold most of the capacity, and the price oscillates around a cost floor set by a petrochemical complex. Eight years of growth at 3.43 per cent is what that structure produces.
A gut-health product is bought to replace something illegal. Its value cannot be calculated against a substitute, because the substitute has been withdrawn. Its effect cannot be measured in a commercial mill, because there is no reference method. Its price is therefore set by what the buyer believes, supported by whatever evidence the supplier can present. Eight years of growth at 8.65 per cent, and a better gross margin than the molecule that can be priced to four decimal places, is what that structure produces.
This is not a criticism of gut-health products. Many of them work. It is an observation about where the pricing power sits, and it has a consequence that the sector has not yet had to price. If buyers ever shift from accepting supplier evidence to demanding independent verification, the third mechanism stops working — not because demand falls, but because the product becomes comparable, and comparables get competed down. Nothing in the current transaction record suggests the market has begun to price that possibility.
What this means for anyone building a forecast
Three practical conclusions follow, and they are the ones we applied in our own model.
Do not use revenue per tonne of feed as a price index. It rises from USD 31.29 to USD 41.14, or 3.48 per cent a year, and almost none of that is like-for-like molecule inflation. It is formulation intensity and mix — more actives, and more expensive ones, per tonne. Treating it as price will make a forecast look precise and be wrong.
Model the categories separately or not at all. The spread between vitamins at 2.64 per cent and gut health at 8.65 per cent is a factor of three. Any single-rate model will misprice both ends.
Watch the authorisation regime, not the demand curve. Demand for feed additives is anchored to protein consumption and is not going to disappear; the industry’s own mill survey has recorded global compound feed output at 1.39 billion tonnes in 2024, up 1.2 per cent. What moves the fastest-growing category is whether its claim survives. That question is examined in the companion article on the 20 January 2026 carvacrol refusal, and it is the one variable in this market that has nothing to do with the animal.
Feed additives are sized in full, with the value chain, competitive landscape, regulatory landscape, investment activity and market risk, in the report on the Global Feed Additives Market. The perimeter excludes inorganic feed phosphates, mycotoxin binders and veterinary medicinal products, each sized separately.
Frequently Asked Questions
Why does the feed additives market have three different price-setting mechanisms instead of one?
Because they are set by different mechanisms. Vitamins and trace elements are bought to a legal minimum, so demand is inelastic and price is set by supply concentration. Amino acids and enzymes are bought as an economic optimum, so their price is capped by the nutrient they replace. Gut-health products are bought to replace something that is no longer legal, so there is no legal substitute to price against and no reference method to verify the effect. Averaging those three into one growth rate produces a forecast that is wrong at both ends.
Is the rise in revenue per tonne of feed a price increase?
No. It rises from USD 31.29 in 2025 to USD 41.14 in 2033, which is 3.48 per cent a year, but the great majority of that is formulation intensity and mix rather than like-for-like molecule inflation. A tonne of feed in 2033 carries more active ingredients, and more expensive ones, than a tonne today. It is a useful measure of value per tonne of feed and a misleading measure of price.
Which category carries the highest supply risk?
Vitamins. Vitamin A and the carotenoids share a synthesis route through citral and isophytol, and when a plant making those precursors stops there is no second source that can be qualified quickly. On 7 August 2024 BASF declared force majeure on selected vitamin A, vitamin E and carotenoid products following a fire at its Ludwigshafen site on 29 July. Nothing about demand changed; a repair schedule at one site became a global formulation constraint. The category's 2.64 per cent average growth is the mean of a series of spikes and reversals.
Why is the fragmented category more profitable than the concentrated one?
Methionine has nine suppliers worldwide producing close to 1.8 to 1.9 million tonnes a year, with the top three holding almost 80 per cent of production and only three of the nine operating more than one plant. Gut health has dozens of participants and no dominant supplier. The fragmented category grows at 8.65 per cent against 3.43 per cent for amino acids and, on participants' own reporting, earns the better gross margin — because its price is not capped by a legal substitute.
